AUTHORS
Joseph Jabbour, Ramza Ishac, MD2, Ghayas C. Issa, MD3, Sanam Loghavi, MD4, Hussein Ali Abbas, MD, PhD5, Yesid Alvarado Valero, MD6, Musa Yilmaz, MD7, Nicholas Short, MD8, Joseph Castellano, MD9, Guillermo Montalban-Bravo, MD10, Maria Villatoro11, Guillermo Garcia-Manero, MD12, Hagop Kantarjian, MD13, Fadi G. Haddad, MD14
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
The presence of ASXL1 mutation in patients with chronic myeloid leukemia in chronic phase (CML-CP) is associated with worse outcomes, including lower molecular response rates and higher rates of treatment failure, irrespective of the tyrosine kinase inhibitor used. Whether the addition of targeted therapies, such as venetoclax or ASTX727 (oral decitabine/cedazuridine) could improve outcomes, remains unknown.
Methods
We reviewed all the patients with newly diagnosed CML-CP treated at our institution on one of three clinical trials with either dasatinib 50 mg/day monotherapy (n=82), dasatinib 50 mg/day + venetoclax (n=66), or dasatinib 50 mg/day + ASTX727 (n=38) and further analyzed those who had targeted next-generation sequencing, using an assay that interrogates genes recurrently mutated in myeloid malignancies, including ASXL1. We then analyzed the molecular response rates of the patients according to the presence or absence of ASXL1 mutation.
Results
A total of 186 patients were included. The median age at the time of CML diagnosis was 46 years (range, 20-84), and 96 (52%) were male. Sokal risk was low in 130 patients (70%), intermediate in 48 (26%), and high in 8 (4%). Mutational analysis was performed in 69 patients (37%), primarily those treated in recent years. By cohort, testing was performed in 30 patients treated with dasatinib + ASTX727 (79%), 23 treated with dasatinib + venetoclax (35%), and 16 treated with dasatinib monotherapy (20%). Among the patients who underwent testing, known pathogenic, somatic ASXL1 mutations were detected in 17% (5/30), 0, and 6% (1/16), respectively.
G646 frameshift(fs) duplication was seen in 3 patients, and G826fs deletion, R774fs duplication, and T639fs duplication, in one patient each. The single patient in the dasatinib monotherapy cohort who had ASXL1 mutation achieved CMR after 6 months of therapy, which was sustained for 5 years, and has been in treatment-free remission (TFR) for 16 months as of the last follow-up.
Five patients with ASXL1 mutations were treated with dasatinib + ASXT727. All 5 patients were in MMR at 12 months, including one patient who achieved CMR. At 24 months, they were all in CCyR, including 1 in MMR, 1 in MR4, and 2 in CMR. Of them, 4 were evaluable at 6 months and were in CMR; the remaining patient has not yet reached the 3-year assessment timepoint.
No loss of response, disease progression, or death were observed among the 6 patients with ASXL1 mutations at the last follow-up.
Since mutational analysis was mostly performed in patients treated with dasatinib + ASTX727, we compared the responses between patients with or without ASXL1 mutation treated on this trial. At 12 months, similar response rates were observed between patients with (n=5) or without (n=24) ASXL1 variants: MMR, 100% vs. 42%; MR4, 20% vs. 25%; and MR4.5, 20% vs. 13%; respectively (P=0.08). At 24 months, these rates were 80% vs. 86%; 60% vs. 48%; and 40% vs. 38%, respectively (P=0.84).
Conclusion
In this study with a limited sample size, ASXL1 mutation was not associated with unfavorable outcomes when treated with dasatinib-based therapy. A larger number of patients is needed to determine the impact of the addition of targeted therapies on the response rates in patients with CML-CP and ASXL1 mutations.
DISCLOSURES
Joseph Jabbour: No relevant conflicts of interest to declare.